¡¡¤ý¡¡Table 1: osteomyelitis, mastitis, brain abscess, encephalitis, meningitis, otitis media, keratitis, gastroenteritis, urethritis, syphilis, pyelonephritis, vaginosis, endocarditis, prosthetic joint, UTIs, pneumonia (esp. GNB), pancreatitis, peritonitis, bites, burns, cellulitis, Lyme, febrile syndromes, sepsis, shock, botulism, IV lines/catheters, vascular
¡¡¤ý¡¡Table 2: resistant bacteria, including GNB
¡¡¤ý¡¡Table 3: duration of therapy
¡¡¤ý¡¡Table 4: organism coverage expanded, drugs added (new and old)
¡¡¤ý¡¡Table 5B: updated treatment options for GNB
¡¡¤ý¡¡Table 6: updated recommendations for management of MRSA
¡¡¤ý¡¡Table 8: pregnancy risk for new drugs
¡¡¤ý¡¡Table 9: PK & interactions data for new drugs added
¡¡¤ý¡¡Table 10: dosing updated and recent drugs added, e.g., plazomicin, eravacycline, omadacycline, temocillin, secnidazole
¡¡¤ý¡¡Table 11: cryptococcosis
¡¡¤ý¡¡Table 12: latent TB, MAC, M. abscessus
¡¡¤ý¡¡Table 13: malaria, tafenoquine
¡¡¤ý¡¡Table 14A: hemorrhagic fevers, influenza
¡¡¤ý¡¡Table 14B: new HCV, CMV drugs
¡¡¤ý¡¡Table 14C: new ARV drugs & combinations, updated recommended ART regimens
¡¡¤ý¡¡Table 14F: updated HCV treatment regimens and recommendations
¡¡¤ý¡¡Table 15: post-exposure prophylaxis
¡¡¤ý¡¡Table 16: added peds dosing for additional antibacterials, ARVs, antivirals
¡¡¤ý¡¡Table 17: renal adjustments for new drugs added
¡¡¤ý¡¡Table 17C: updated obesity dose adjustments
¡¡¤ý¡¡Table 22: DDIs completely reworked to focus on effects and suggested management |